GlassScriptPhysician profile
Jonathan B Covey
NPI 1639105638
$7,945.48
in general payments reported to CMS, 2019-2025
24 companies · $2,393 in 2025
The $2,393 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,065 · 2020: $261 · 2021: $882 · 2022: $938 · 2023: $893 · 2024: $1,514 · 2025: $2,393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,672 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,672.24 |
| Education | $127.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,712.74 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,433.98 | 2021-2025 | Vraylar |
| Alkermes, INC. | $805.87 | 2019-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $556.64 | 2019-2025 | Ingrezza |
| Allergan, INC. | $524.41 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $515.55 | 2019-2025 | Austedo Xr, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $452.33 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $336.51 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $291.92 | 2021-2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $252.71 | 2022-2024 | Quviviq |
| Eisai INC. | $229.53 | 2021-2022 | |
| Harmony Biosciences LLC | $191.62 | 2025 | |
| Axsome Therapeutics, INC. | $150.18 | 2024-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $122.79 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $65.28 | 2019-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $61.41 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $48.58 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $44.60 | 2021-2022 | |
| Bausch Health US, LLC | $35.00 | 2019 | |
| Sage Therapeutics, LLC | $29.70 | 2024 | |
| Almatica Pharma LLC | $25.65 | 2025 | Loreev Xr |
| Adlon Therapeutics L.P. | $21.55 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.19 | 2025 | Trintellix |
| Tempus Ai, INC | $15.74 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Covey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.